Equity Profile

BMRN

BioMarin Pharmaceutical Inc.

Health CareBiotechnology$11.1B

May4Mon

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

BioMarin Pharmaceutical Inc. Misses on EPS, Stock Up 2.59%

Metric	Actual	Expected	Surprise
EPS	$0.76	$0.97	-2.44%
Revenue	N/A	$754M	N/A

management commentary, guidance changes, and full analysis available with Pro.

BioMarin Pharmaceutical Inc. Misses on EPS, Stock Up 2.59%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.76	$0.97	-2.44%
Revenue	N/A	$754M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

BioMarin's earnings report showed a miss on EPS compared to expectations, which could raise concerns among investors. However, the stock reacted positively, increasing by 2.59%. This increase may reflect investor optimism despite the earnings miss, possibly due to other underlying factors not detailed in the earnings call.

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions....

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health.

$0.97

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$754M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. Operating in the health care sector, BioMarin is particularly known for its treatments for rare genetic disorders, making it a key player in the biotechnology industry.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q4 2025, BioMarin reported an EPS of $0.46, significantly exceeding expectations. However, the stock saw a decline of 1.81% the following day, indicating market skepticism despite the positive earnings surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BioMarin to report solid earnings this quarter, with a consensus EPS of $0.97. The market is closely watching how the company performs against these expectations, especially given its mixed earnings history.

Bull Case

If BioMarin can meet or exceed the EPS estimate, it could signal strong demand for its products and boost investor confidence, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses earnings expectations, it could raise concerns about its growth prospects and lead to a significant drop in the stock price.

Key Metrics to Watch

EPS

$0.97

Earnings per share is a crucial indicator of the company's profitability and financial health.

Revenue

$754M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioMarin achieve an EPS of $0.97 or higher?

This figure is critical as it will determine whether the company meets market expectations and influences investor sentiment.

What are the revenue figures compared to the consensus of $754M?

Revenue performance will provide insights into the demand for BioMarin's products and its overall market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioMarin to exceed EPS expectations due to recent product launches that have not been fully accounted for.

Supporting Evidence

The company has a strong history of beating EPS estimates, with an 88% success rate over the last eight quarters.

Recent product performance suggests higher sales than analysts anticipate, particularly in the rare disease segment.

Key Risk

If revenue comes in below $700M, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether BioMarin can sustain its growth amid competitive pressures and evolving market conditions.

Bull Confirmed If

An EPS of $1.00 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $0.74 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±9.06%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move for BioMarin's stock, indicating that traders expect volatility around the earnings report.

Options are pricing ±9.1% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

25.6%

Calls (17K)P/C Ratio: 0.05Puts (9K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests the stock could rise by around 3.73%, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately 3.32%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product launch timelines and their expected impact on revenue.
2Details on sales growth in key therapeutic areas.
3Management's outlook on competitive pressures in the biotechnology sector.
4Insights into research and development progress for upcoming therapies.
5Any commentary on regulatory challenges that could affect future product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions....

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health.

$0.97

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$754M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioMarin can meet or exceed the EPS estimate, it could signal strong demand for its products and boost investor confidence, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses earnings expectations, it could raise concerns about its growth prospects and lead to a significant drop in the stock price.

Key Metrics to Watch

EPS

$0.97

Earnings per share is a crucial indicator of the company's profitability and financial health.

Revenue

$754M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioMarin achieve an EPS of $0.97 or higher?

This figure is critical as it will determine whether the company meets market expectations and influences investor sentiment.

What are the revenue figures compared to the consensus of $754M?

Revenue performance will provide insights into the demand for BioMarin's products and its overall market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioMarin to exceed EPS expectations due to recent product launches that have not been fully accounted for.

Supporting Evidence

The company has a strong history of beating EPS estimates, with an 88% success rate over the last eight quarters.

Recent product performance suggests higher sales than analysts anticipate, particularly in the rare disease segment.

Key Risk

If revenue comes in below $700M, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether BioMarin can sustain its growth amid competitive pressures and evolving market conditions.

Bull Confirmed If

An EPS of $1.00 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $0.74 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±9.06%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move for BioMarin's stock, indicating that traders expect volatility around the earnings report.

Options are pricing ±9.1% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

25.6%

Calls (17K)P/C Ratio: 0.05Puts (9K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests the stock could rise by around 3.73%, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately 3.32%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product launch timelines and their expected impact on revenue.
2Details on sales growth in key therapeutic areas.
3Management's outlook on competitive pressures in the biotechnology sector.
4Insights into research and development progress for upcoming therapies.
5Any commentary on regulatory challenges that could affect future product approvals.